低风险甲状腺微小乳头状癌的射频消融:一项随访超过10年的回顾性队列研究
该回顾性队列纳入65例低风险甲状腺微小乳头状癌患者(71个病灶),随访中位151个月,评估超声引导下射频消融的长期疗效与安全性。结果显示无疾病进展,但7.7%患者出现新发甲状腺乳头状癌,完全消失率在24个月达100%。
要点
- 低风险甲状腺微小乳头状癌射频消融后中位随访151个月,无疾病进展。
- 7.7%(5/65)患者出现新发甲状腺乳头状癌,其中4例再次射频消融、1例肺叶切除。
- 完全肿瘤消失率在6、12、24个月分别为40.8%、74.6%、100%。
核心结论
- 作者经验认为,低风险甲状腺微小乳头状癌的射频消融有效且安全;随访超过10年未见局部肿瘤进展或转移,但7.7%患者出现新发甲状腺乳头状癌。
研究设计与样本
- 回顾性队列研究,纳入2008年5月至2013年12月间接受超声引导下射频消融、随访超过10年的低风险甲状腺微小乳头状癌患者65例(71个病灶)。
- 患者为不适合手术或拒绝手术者;首次射频消融因肿瘤紧贴喉返神经未能获得足够安全边缘时,行分期射频消融。
主要发现
- 中位随访151个月(四分位距131-157),每肿瘤平均射频消融次数1.2次,20%(13/65)患者需重复射频消融。
- 无疾病进展病例;5例(5/65,7.7%)出现新发甲状腺乳头状癌,其中4例接受射频消融、1例接受肺叶切除。
- 24个月时平均体积缩小率为100%,并维持至末次随访。
- 一次或多次射频消融后完全肿瘤消失率在6、12、24个月分别为40.8%(29/71)、74.6%(53/71)、100%(71/71)。
- 发生1例主要不良事件(亚临床甲状腺功能减退)和3例次要不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The longest reported follow-up for thermal ablation of papillary thyroid microcarcinoma (PTMC) is 5 years. We evaluated the long-term efficacy and safety of radiofrequency ablation (RFA) in patients with low-risk PTMC with clinical follow-up of more than 10 years. Methods: In this retrospective cohort study, we included patients with low-risk PTMC who had more than 10 years of follow-up after ultrasound (US)-guided RFA (performed between May 2008 and December 2013). Sixty-five consecutive patients with 71 low-risk PTMCs who were unsuitable for surgery or declined surgery were included. Before RFA, all patients underwent US and thyroid computerized tomography. Repeat RFA for staged ablation was performed when the first RFA did not secure sufficient safety margins because of the tumor closely abutting the recurrent laryngeal nerve. Follow-up US imaging was performed at 1 week, 3 months, 6 months, every 6 months until 2 years, and then annually afterward. Primary outcomes were the respective cumulative rates of disease progression (defined by local tumor progression, lymph node, or distant metastasis), newly developed thyroid cancer, and conversion surgery. Secondary outcomes were serial volume reduction rate (VRR), complete disappearance rate of ablated PTMC, and adverse events associated with procedures. Results: Of 65 patients included in the study, 60 had unifocal and 5 had multifocal PTMCs. The mean number of RFA sessions per tumor was 1.2, and the median follow-up duration was 151 months (interquartile ranges, 131-157). Twenty percent (13/65) of patients required repeat RFA. There were no cases of disease progression. Five patients (5/65, 7.7%) developed a new papillary thyroid cancer (four treated with RFA and one with lobectomy). At 24 months, the mean VRR was 100%, and this was maintained throughout the final follow-up. The complete tumor disappearance rates after one or more RFA treatments were 40.8% (29/71), 74.6% (53/71), and 100% (71/71) at 6, 12, and 24 months, respectively. One major (subclinical hypothyroidism) and three minor adverse events occurred. Conclusions: In our experience, RFA of low-risk PTMC is effective and safe. During more than 10 years of follow-up, we observed no incident local tumor progression nor metastases, but 7.7% of patients developed a new papillary thyroid cancer.
引用
- Jeong SY, Baek SM, Shin S, et al. Radiofrequency Ablation of Low-Risk Papillary Thyroid Microcarcinoma: A Retrospective Cohort Study Including Patients with More than 10 Years of Follow-up. Thyroid. 2025. PMID: 39868683. doi:10.1089/thy.2024.0535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。